Sharon Yeatts to Young Adult
This is a "connection" page, showing publications Sharon Yeatts has written about Young Adult.
Connection Strength
0.275
-
Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med. 2021 11 18; 385(21):1951-1960.
Score: 0.022
-
Progesterone Treatment Does Not Decrease Serum Levels of Biomarkers of Glial and Neuronal Cell Injury in Moderate and Severe Traumatic Brain Injury Subjects: A Secondary Analysis of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III Trial. J Neurotrauma. 2021 07 15; 38(14):1953-1960.
Score: 0.021
-
Association of Very Early Serum Levels of S100B, Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and Spectrin Breakdown Product with Outcome in ProTECT III. J Neurotrauma. 2019 10 15; 36(20):2863-2871.
Score: 0.019
-
Association of Thrombectomy With Stroke Outcomes Among Patient Subgroups: Secondary Analyses of the DEFUSE 3 Randomized Clinical Trial. JAMA Neurol. 2019 04 01; 76(4):447-453.
Score: 0.019
-
Prehospital Intubation is Associated with Favorable Outcomes and Lower Mortality in ProTECT III. Prehosp Emerg Care. 2017 Sep-Oct; 21(5):539-544.
Score: 0.017
-
A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3). Int J Stroke. 2017 10; 12(8):896-905.
Score: 0.016
-
Very Early Administration of Progesterone Does Not Improve Neuropsychological Outcomes in Subjects with Moderate to Severe Traumatic Brain Injury. J Neurotrauma. 2017 01 01; 34(1):115-120.
Score: 0.015
-
Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial. Stroke. 2015 Aug; 46(8):2142-8.
Score: 0.015
-
Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1321-7.
Score: 0.014
-
Very early administration of progesterone for acute traumatic brain injury. N Engl J Med. 2014 Dec 25; 371(26):2457-66.
Score: 0.014
-
Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions. J Neurointerv Surg. 2015 Nov; 7(11):795-802.
Score: 0.014
-
Evolution of practice during the Interventional Management of Stroke III Trial and implications for ongoing trials. Stroke. 2014 Dec; 45(12):3606-11.
Score: 0.014
-
Early reperfusion and clinical outcomes in patients with M2 occlusion: pooled analysis of the PROACT II, IMS, and IMS II studies. J Neurosurg. 2014 Dec; 121(6):1354-8.
Score: 0.014
-
Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):567-74.
Score: 0.013
-
Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke. 2014 Mar; 45(3):759-64.
Score: 0.013
-
High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocrit Care. 2013 Oct; 19(2):257-66.
Score: 0.013
-
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 07; 368(10):893-903.
Score: 0.012
-
Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009 Sep 29; 73(13):1066-72.
Score: 0.010